KLRC1 and neoplasm: To exclude that the greater efficacy of the combination of mAbs was not simply due to a dose effect, we gave anti‐NKG2A mAb at 100 μg, but still the combination of anti‐NKG2A (30 μg) + anti‐Qa1b (30 μg) attained better tumor control than the higher dose of anti‐NKG2A in the same experimental setting (Fig EV4).